Published onVaccine Update for Healthcare Providers
People with immune-compromising conditions account for approximately 3% of the population. To determine the relative efficacy of vaccines to prevent hospitalizations in immune-compromised versus immune-competent people, researchers from several academic centers compared 20,000 immune-compromised adults with 69,000 immune-competent adults, all of whom had received at least two doses of mRNA-containing vaccine at least 14 days earlier (Embi PJ, Levy ME, Naleway AL, et. Al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults — Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1553-1559).
Vaccine efficacy of two doses of mRNA-containing vaccines for prevention of hospitalization was 77% among immune-compromised adults and 90% among immune-competent adults. Vaccine efficacy varied among immune-compromised adults based on their immune-compromising condition, ranging from 59% efficacy for recipients of solid organ or bone marrow transplants to 81% efficacy for those with rheumatologic or other inflammatory disorders.
Currently, those who are immune compromised are recommended to receive three doses of mRNA-containing vaccine.
Materials in this section are updated as new information and vaccines become available. The Vaccine Education Center staff regularly reviews materials for accuracy.
You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family's personal health. You should not use it to replace any relationship with a physician or other qualified healthcare professional. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult your physician or, in serious cases, seek immediate assistance from emergency personnel.